Guardion Health Sciences Inc Share Price Nasdaq
Equities
US40145Q2030
Pharmaceuticals
Sales 2024 * | 13.45M 1.12B | Sales 2025 * | 14.8M 1.23B | Capitalization | 11.9M 990M |
---|---|---|---|---|---|
Net income 2024 * | -3M -250M | Net income 2025 * | -3M -250M | EV / Sales 2024 * | 0.88 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.8 x |
P/E ratio 2024 * |
-3.86
x | P/E ratio 2025 * |
-9.08
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.71% |
Managers | Title | Age | Since |
---|---|---|---|
Jan Hall
CEO | Chief Executive Officer | - | 19/23/19 |
Chairman | 72 | 30/15/30 | |
Katie Cox
AUD | Comptroller/Controller/Auditor | - | 25/23/25 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 72 | 30/15/30 | |
Mark Goldstone
BRD | Director/Board Member | 60 | 01/15/01 |
Donald Gagliano
BRD | Director/Board Member | 71 | 09/19/09 |
1st Jan change | Capi. | |
---|---|---|
+37.78% | 723B | |
+31.69% | 598B | |
-3.51% | 364B | |
+19.94% | 331B | |
+5.14% | 288B | |
+16.06% | 244B | |
-4.42% | 208B | |
+10.18% | 210B | |
+9.32% | 169B |